Alberti W, Greber H, John V, Wessing A, Scherer E
Strahlentherapie. 1983 Mar;159(3):160-7.
For the first time, a report is given on the percutaneous radiotherapy of hemangiomas of the choroid which could not be treated by photocoagulation. Diagnosis and control examinations of these tumors were performed by ophthalmoscopy, fluorescence angiography, and ultrasonography. Ten eyes (nine patients, three out of them with Sturge-Weber's disease) were treated between 1967 and 1982. A first group (five eyes, five patients) treated until 1974 received a target volume dose of 1,65 to 6,5 Gy combined with subsequent photocoagulation. All these eyes could be preserved. In addition, the second group (five eyes, four patients) treated since 1975 with unique radiotherapy showed better results with respect to visual acuity. The average follow-up period was four years (seven months up to nine years). Late effects were not observed. Even in case of advanced disease with retinal ablation and secondary glaucoma, an inactivation of the hemangioma of the choroid and a simultaneous regression of the secondary alterations could be achieved. According to our experiences, enucleations can be prevented by an irradiation with a target volume dose of 20 to 30 Gy.
首次报道了对不能用光凝治疗的脉络膜血管瘤进行经皮放射治疗。通过检眼镜检查、荧光血管造影和超声检查对这些肿瘤进行诊断和对照检查。1967年至1982年间，对10只眼（9例患者，其中3例患有斯-韦二氏病）进行了治疗。第一组（5只眼，5例患者）在1974年之前接受治疗，靶体积剂量为1.65至6.5戈瑞，并随后进行光凝。所有这些眼睛均得以保留。此外，自1975年起接受单纯放射治疗的第二组（5只眼，4例患者）在视力方面显示出更好的效果。平均随访期为4年（7个月至9年）。未观察到晚期效应。即使在患有视网膜脱离和继发性青光眼的晚期疾病情况下，也能实现脉络膜血管瘤的灭活以及继发性病变的同时消退。根据我们的经验，通过给予20至30戈瑞的靶体积剂量照射可以避免眼球摘除。
